Equatorial Guinea vs Morocco: Statin use vs. average non-HDL cholesterol levels
Equatorial Guinea
2.8
in 2018
Morocco
2.8
in 2018
Equatorial Guinea rank
163rd
Morocco rank
163rd
Statin use vs. average non-HDL cholesterol levels over time
- Equatorial Guinea
- Morocco
How they compare
Equatorial Guinea currently reports 2.8 against 2.8 in Morocco, a difference of 0.
Across all 39 years both countries report, Morocco has been ahead every year.
Equatorial Guinea ranks 163rd and Morocco ranks 163rd of 191 countries.
Morocco has averaged higher in every one of the 4 decades both report.
Head to head by decade
| Decade | Equatorial Guinea | Morocco | Difference | Ahead |
|---|---|---|---|---|
| 1980s | 2.59 | 3.01 | 0.42 | Morocco |
| 1990s | 2.73 | 3.27 | 0.54 | Morocco |
| 2000s | 2.82 | 3.25 | 0.43 | Morocco |
| 2010s | 2.86 | 2.96 | 0.1 | Morocco |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher statin use vs. average non-hdl cholesterol levels, Equatorial Guinea or Morocco?
- Equatorial Guinea, at 2.8 against 2.8 in Morocco as of 2018.
- What is the difference in statin use vs. average non-hdl cholesterol levels between Equatorial Guinea and Morocco?
- 0, with Equatorial Guinea ahead.
- How many years of comparable data are there for Equatorial Guinea and Morocco?
- 39 years are reported by both, from 1980 to 2018.
- How do Equatorial Guinea and Morocco rank globally for statin use vs. average non-hdl cholesterol levels?
- Equatorial Guinea ranks 163rd and Morocco ranks 163rd of 191 countries.
- Where does this data come from?
- World Health Organization – Global Health Observatory (2026) – with minor processing by Our World in Data, published as Statin use vs. average non-HDL cholesterol levels. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
The use of statins in the population. This is compared to average non-HDL cholesterol levels, in mmol/L. Statins are a type of drug that reduce non-HDL cholesterol levels, and are used to treat and prevent cardiovascular diseases in people at heightened risk. Their usage is measured in Defined Daily Doses, per 1,000 people.